Loading…
Please register to continue your trial period!
meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
In the context of Ipilimumab + Nivolumab & Pleural mesothelioma, Ipilimumab + Nivolumab is approved by both the FDA and EMA as first‑line treatment for adults with unresectable malignant pleural mesothelioma (1, 2).
In a clinical phase III trial identified as NCT02899299, it was found that the combination Ipilimumab + Nivolumab led to statistically significant and clinically meaningful improvements in overall survival when compared to the standard-of-care chemotherapy. This supports the use of this first-in-class regimen,…